桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2026-005 桂林莱茵生物科技股份有限公司 关于公司控制权变更、发行股份购买资产并募集配套资金 暨关联交易事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、桂林莱茵生物科技股份有限公司（以下简称"公司"）于2025年12月24 日披露了《关于控股股东签署<控制权变更框架协议><股份转让协议><表决权放 弃协议><不谋求控制权承诺函>及公司签署<发行股份购买资产协议><附条件生 效的股份认购协议><股权转让协议>暨控制权拟发生变更的提示性公告》（公告 编号：2025-076）、《桂林莱茵生物科技股份有限公司发行股份购买资产并募集 配套资金暨关联交易预案》（以下简称"《交易预案》"）及其摘要，在上述披 露文件中对本次控制权变更、发行股份购买资产并募集配套资金事项（以下统称 "本次交易"）所涉及的有关风险因素及尚需履行的审批程序进行了详细说明， 敬请广大投资者注意投资风险。 公司拟向德福金康普控股有限合伙企业、厦门德福金普投资合伙企业（有限 合伙）发 ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2026-004 桂林莱茵生物科技股份有限公司 关于股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）董事会近日接到大股 东秦本军先生的通知，获悉秦本军先生向国海证券股份有限公司（以下简称"国 海证券"）偿还了部分融资借款，并将其所持有的部分公司股份办理了解除质押 手续，现将具体情况公告如下： 注：表中数值若出现总数与各分项数值之和尾数不符，均为四舍五入原因所致（下同）。 截至本公告披露日，秦本军先生资信状况良好，具备履约能力，其所质押的 1 股东 名称 是否为控股股 东或第一大股 东及其一致行 动人 本次解除 质押股份 数量 （万股） 占其所持 公司股份 比例（%） 占公司 总股本 比例 （%） 质押 起始日 质押 解除日 质权 人 秦本军 是 6,800.00 25.06 9.17 2022 年 7 月 28 日 2026 年 3 月 3 日 国海 证券 一、股东解除质押的基本情况 桂林莱茵生物科技股 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、桂林莱茵生物科技股份有限公司（以下简称"公司"）于2025年12月24日披露了《关于控股股东签署 〈控制权变更框架协议〉〈股份转让协议〉〈表决权放弃协议〉〈不谋求控制权承诺函〉及公司签署 〈发行股份购买资产协议〉〈附条件生效的股份认购协议〉〈股权转让协议〉暨控制权拟发生变更的提 示性公告》（公告编号：2025-076）、《桂林莱茵生物科技股份有限公司发行股份购买资产并募集配套 资金暨关联交易预案》（以下简称"《交易预案》"）及其摘要，在上述披露文件中对本次控制权变更、 发行股份购买资产并募集配套资金事项（以下统称"本次交易"）所涉及的有关风险因素及尚需履行的审 批程序进行了详细说明，敬请广大投资者注意投资风险。 2、自本次交易披露以来，公司及相关各方积极推进本次交易所涉及的股份协议转让，标的公司尽职调 查、审计和评估等各项工作。截至本公告披露之日，上述工作正按计划有序推进中。公司将在相关工作 全部完成后，再次召开董事会审议本次交易的相关事项，并依照 ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2026-003 桂林莱茵生物科技股份有限公司 关于公司控制权变更、发行股份购买资产并募集配套资金 暨关联交易事项的进展公告 （一）公司控股股东发生变更的具体情况 2025年12月22日，公司原控股股东、实际控制人秦本军先生与广州德福营养 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、桂林莱茵生物科技股份有限公司（以下简称"公司"）于2025年12月24 日披露了《关于控股股东签署<控制权变更框架协议><股份转让协议><表决权放 弃协议><不谋求控制权承诺函>及公司签署<发行股份购买资产协议><附条件生 效的股份认购协议><股权转让协议>暨控制权拟发生变更的提示性公告》（公告 编号：2025-076）、《桂林莱茵生物科技股份有限公司发行股份购买资产并募集 配套资金暨关联交易预案》（以下简称"《交易预案》"）及其摘要，在上述披 露文件中对本次控制权变更、发行股份购买资产并募集配套资金事项（以下统称 "本次交易"）所涉及的有关风险因素及尚需履行的审批程序进行了 ...

Core Viewpoint - The article highlights a significant trend in the A-share market, where there has been a surge in control changes among listed companies, reflecting increased market activity and strategic repositioning by various stakeholders [2][12]. Group 1: Control Changes in Listed Companies - Since 2025, at least 150 listed companies have announced plans for control changes, averaging one company every two days [2][3]. - As of 2026, over 60 companies have reported progress on control changes, indicating a continuation of this trend [2]. - The majority of control changes are occurring in traditional industries such as chemicals, textiles, and consumer goods, with acquirers including individuals, state-owned enterprises, and investment firms [2][5]. Group 2: Industry Distribution of Control Changes - The distribution of control changes shows that traditional industries dominate, with 12.77% of changes in the oil and petrochemical sector, and significant activity in environmental services, construction, and light manufacturing [5][7]. - Other sectors like agriculture, textiles, and real estate also show notable percentages of control changes, indicating a broad impact across various industries [5][7]. Group 3: Market Capitalization of Companies Involved - A significant portion of companies undergoing control changes are small-cap firms, with 169 companies having a market capitalization below 10 billion yuan, accounting for nearly 80% of the total [8][9]. - Companies with a market cap below 5 billion yuan represent 47.44%, while those between 5 billion and 10 billion yuan make up 31.16% [9][10]. Group 4: Motivations Behind Control Changes - The motivations for these control changes include financial distress among original controlling shareholders, strategic shifts in traditional industries, and pressures from debt [12][14]. - The trend is also driven by the need for new capital and resources to enhance company governance and operational efficiency [11][12]. Group 5: Types of Acquirers - The acquirers in these control changes are primarily state-owned enterprises, industrial capital, and limited partnership firms, with state-owned entities frequently taking over to optimize industrial layouts and stabilize the market [14]. - Industrial capital is also a significant player, often seeking to enhance synergies and expand into new business areas [14].

Core Viewpoint - The company is undergoing a change in control and asset acquisition, aiming for vertical integration of its supply chain through the acquisition of 95.5% of Beijing Jinkangpu's shares [1][2]. Group 1: Control Change and Management - The company plans to resume trading on December 24, 2025, and will initiate a control change and a comprehensive transaction plan [2]. - The original controlling shareholder intends to transfer 8.09% of shares and relinquish voting rights for 25.5% of shares, with Guangzhou Defu Nutrition Investment Partnership becoming the new controlling shareholder [2]. - As of February 10, 2026, the share transfer agreement and asset audit are progressing as planned, with the company committing to disclose updates every 30 days [2]. Group 2: Project Advancement - The acquisition is aimed at downstream vertical integration, focusing on synergy in technology, market, and raw materials [3]. - Beijing Jinkangpu possesses advantages in formula development and customer networks, which may enhance the company's application solution capabilities and customer loyalty post-acquisition [3]. - The effectiveness of the integration and the pace of business expansion will be key areas for long-term observation [3]. Group 3: Strategic Development - The company will continue to focus on high-quality market targets around its core business of natural health ingredients, considering both horizontal and vertical integration opportunities [4]. - The resources from Defu Capital may facilitate the company's transformation from a raw material supplier to a platform enterprise, potentially leading to governance optimization and resource integration [4]. Group 4: Capacity Expansion - The company has completed global capacity layout, but the new factories have a short operational history, resulting in low current capacity utilization [5]. - Future capacity release will depend on sales growth of core products, expansion into new categories, and the rollout of synthetic biology technology products [5].

Core Viewpoint - The collaboration between Rhein Biotech and Defo Capital is driven by a shared vision for the natural health ingredients sector and mutual recognition of strategic alignment [1] Group 1: Strategic Alignment - Both Defo Capital and Rhein Biotech have a strong belief in the potential of the natural health ingredients niche, which forms the foundation for their partnership [1] - The strategic alignment and shared philosophy between the two entities are key drivers for the collaboration [1] Group 2: Comprehensive Advantages - Rhein Biotech has over 20 years of industry experience, which contributes to its strong market position and comprehensive advantages that Defo Capital considered [1] - The company has a well-established industrial layout, sufficient production capacity, leading production technology, and a robust quality control system [1] - Rhein Biotech's global sales network and solid governance structure provide a strong foundation for its development [1] Group 3: Product Development Capabilities - The company possesses systematic capabilities in product selection, expansion, and incubation, supported by a complete R&D and industrialization chain [1] - This capability allows for efficient transformation of products from concept to market [1] Group 4: Technological Advancement - Rhein Biotech demonstrates a strong internal drive for business upgrades and technological iteration, maintaining a keen awareness of technological advancements [1] - The company has proactively engaged in cutting-edge fields such as synthetic biology and formulation applications, successfully achieving technological upgrades [1] - Rhein Biotech is actively exploring diverse application scenarios, including animal feed and pet nutrition, showcasing its growth potential and vitality [1]

Core Viewpoint - The collaboration between Rhein Biotech and Defo Capital is driven by a shared strategic vision and mutual recognition of the potential in the natural health ingredients sector [1] Group 1: Strategic Alignment - Both Defo Capital and Rhein Biotech have a strong belief in the natural health ingredients niche, which forms the foundation of their partnership [1] - The strategic alignment and shared philosophy between the two entities are key drivers for the collaboration [1] Group 2: Comprehensive Advantages - Rhein Biotech has over 20 years of industry experience, establishing a solid industry position and comprehensive advantages that attracted Defo Capital [1] - The company boasts a well-rounded industrial layout, robust production capacity, leading production technology, and a global sales network, ensuring a strong operational foundation [1] - Rhein Biotech possesses systematic capabilities in product selection, development, and incubation, enabling efficient transformation from concept to market [1] Group 3: Continuous Business Upgrades - The company demonstrates an internal drive for continuous business upgrades and technological iterations, maintaining a keen awareness of technological advancements [1] - Rhein Biotech has proactively ventured into cutting-edge fields such as synthetic biology and formulation applications, successfully achieving technological upgrades [1] - The company is actively exploring diverse application scenarios, including animal feed and pet nutrition, showcasing its growth vitality and potential [1]

Group 1: Transaction Overview - The transaction with Defo Capital involves the transfer of 8.09% equity from the original controlling shareholder and the acquisition of 95.5% equity in Beijing Jinkangpu, aimed at vertical integration in the industry [3][4] - The acquisition is expected to enhance the company's capabilities in customer service, channel diversification, and resource integration, providing strong support for future development [2][3] Group 2: Strategic Alignment - Defo Capital's focus on the health sector aligns with the company's strategic direction, recognizing the potential in natural health components [4][5] - The company has over 20 years of industry experience, a robust production capacity, and a comprehensive quality control system, making it an attractive partner for Defo Capital [5][6] Group 3: Business Development Plans - The company plans to focus on two main directions for its synthetic biology business: developing proprietary products and providing industrialization services for external clients [6][7] - The RM2 product, a key natural sweetener, is expected to reshape the market, with plans for promotion through high-quality product and formulation services [7][8] Group 4: Capacity and Utilization - The company has established multiple extraction facilities, ensuring sufficient capacity, but current utilization rates are low due to new facilities not yet being operational [8][9] - Future capacity release will depend on sales growth of core products and the introduction of new synthetic biology products into the market [9][10] Group 5: Global Operations - The upgrade of the U.S. extraction facility aims to enhance supply chain security and meet global customer demands, focusing on producing raw materials advantageous in North America [9][10] - The company plans to optimize overseas capacity and improve product delivery efficiency to achieve significant operational improvements in the U.S. market [9]

Core Insights - The Chinese red date extract market is projected to reach 1.197 billion yuan in 2024, reflecting a year-on-year increase of 5.3% driven by health consumption upgrades, policy support, and technological innovation [1][13][14] Market Overview - The red date extract is derived from the fruit of red dates and is primarily used in pharmaceuticals, health products, beverages, and food additives. It is characterized by a brownish-yellow to brown powder with a sweet taste, containing alkaloids, sugars, organic acids, and vitamins, which provide health benefits such as nourishing the body, regulating endocrine functions, enhancing immunity, and improving blood circulation [3][4] Industry Chain - The red date extract industry chain consists of three segments: - Upstream: Focuses on red date cultivation, agricultural supply, and initial processing equipment manufacturing, with major production concentrated in regions like Xinjiang, Hebei, Shandong, Shaanxi, and Shanxi [7][8] - Midstream: Involves the procurement, processing, and extraction of red dates [8] - Downstream: Encompasses applications in food and beverages, dietary supplements, cosmetics, and pharmaceuticals, catering to consumer demands for natural and healthy products [8][10] Competitive Landscape - The red date extract industry is characterized by a "leading enterprises dominate, small and medium enterprises differentiate" structure. Leading companies leverage their R&D capabilities and full industry chain advantages to maintain market dominance, while smaller firms focus on niche markets and differentiated services [14][15] Development Trends - The application of red date extract is expected to deepen across various sectors: - In the food sector, there will be a shift towards developing functional foods tailored for specific demographics such as the elderly and athletes [17] - In cosmetics, the extract's antioxidant and moisturizing properties will see broader applications in skincare products [17] - In pharmaceuticals, the extract's medicinal value will be further explored for potential use in treatments for cardiovascular issues and immune enhancement [17] Sustainability and Green Production - The industry will increasingly emphasize sustainable development and green production practices, promoting eco-friendly cultivation methods and optimizing resource utilization during production to minimize environmental impact [18] International Market Expansion - Companies will accelerate their international market strategies, responding to growing demand for natural health products in regions like North America and Europe, while leveraging e-commerce to enhance global reach [19]